US EditionFosun Pharma Announces 2024 Annual Results
- Fosun Pharma reported operating revenue of RMB41.07 billion and a net profit of RMB2.77 billion for 2024, marking a 16.08% year-on-year increase.
- The company launched seven innovative products and has over 80 projects in its drug pipeline, focusing on R&D expenditures totaling RMB5.55 billion in 2024.
- Fosun Pharma’s innovative anti-PD-1 monoclonal antibody, Han Si Zhuang, is now approved in over 30 countries and benefits more than 100,000 patients worldwide.
- Chairman Wu Yifang stated they aim to lead in healthcare innovation while addressing unmet clinical needs and enhancing global expansion.
Insights by Ground AI
Does this summary seem wrong?
61 Articles
61 Articles
All
Left
4
Center
19
Right
6
Charleston Gazette-Mail+59 Reposted by 59 other sources
Fosun Pharma Announces 2024 Annual Results
Accelerates Globalization of Innovative Products with Operating Cash Flow Surging 31.13% YoY
·Charleston, United States
Read Full Article
Fosun’s Core Businesses Stay Firm Despite One-off Non-cash Loss – DIR HONGKONG
HONG KONG, Mar 31, 2025 – (ACN Newswire via SeaPRwire.com) – On 30 March, Fosun International (00656) announced its 2024 annual results, reporting a total revenue of RMB192.14 billion. The Group’s four core subsidiaries – Yuyuan, Fosun Pharma, Fosun Insurance Portugal, and Fosun Tourism Group (“FTG”) – generated a total revenue of RMB134.65 billion, accounting for 70.1% of the Group’s total revenue. The loss attributable to owners of the parent …
Coverage Details
Total News Sources61
Leaning Left4Leaning Right6Center19Last UpdatedBias Distribution66% Center
Bias Distribution
- 66% of the sources are Center
66% Center
14%
C 66%
R 21%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
